



Bachem switching from IFRS to Swiss GAAP FER

Bubendorf/Basel, April 25, 2013 – The Board of Directors of Bachem Holding AG (SIX: BANB) passed a resolution at its meeting yesterday to switch the company's accounting standards from IFRS to Swiss GAAP FER. It intends to make the switch retroactive to January 1, 2013. The registered shares of Bachem Holding AG will remain listed on the SIX Swiss Exchange. A request to have the company shares transferred from the Main Standard to the Domestic Standard will be submitted to the SIX Swiss Exchange Regulation.

The growing body of rules and regulations under the previously applied International Financial Reporting Standards (IFRS) is leading to increasingly complex financial disclosure requirements. These standards are imposing more and more detailed formal requirements that, for the most part, do not lead to a better understanding of the company's financial position and operating results. On the other hand, they are causing additional administrative costs. With this decision to switch to Swiss GAAP FER, Bachem will be applying accounting standards with comparable informative value. The new standards will likewise ensure transparency in future reporting periods. The half-year report for 2013 will be prepared according to the new standards.

About Bachem

Bachem is an independent, technology-based, public biochemicals company providing full service to the pharma and biotech industry. Bachem is specialized in the process development and the manufacturing of peptides and complex organic molecules as active pharmaceutical ingredients (APIs), as well as innovative biochemicals for research purposes. With headquarters in Bubendorf, Switzerland, and affiliates in Europe and the US, Bachem works on a global scale and holds a leading position in the field of peptides.

For more information:

Bachem Holding AG
Stephan Schindler, CFO
Tel.: +41 61 935 2333
Fax: +41 61 935 2324

www.bachem.com
ir@bachem.com